Wednesday, November 18, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
How to earnPaparazzi InkBack PageHolder perksLeaderboardAssignmentsContestsLeagueCity
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsCity LeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundToken utilityRobinhood Chain launchesRobinhood Chain projectsPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 58

GSK's Nelkarmi wins FDA nod for ALK lung cancer, capping a three-approval run

The FDA cleared Nelkarmi for previously treated ALK-positive non-small cell lung cancer, giving GSK its second commercial lung cancer drug and the second to come out of its $10.6 billion Nuvalent buy. It landed ahead of the agency's Nov. 27 target date and marks GSK's third high-profile approval in weeks.

By the Paparazzi desk November 17, 2026 · 5:30 AM · fiercepharma.com · 1 view
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: fiercepharma.com.
  • The source published it on Nov 17, 2026 at 5:30 AM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

GSK has nabbed FDA approval for Nelkarmi, or neladalkib, in previously treated ALK-positive non-small cell lung cancer. It's only the second commercial lung cancer drug in the British pharma's history, and the second to emerge from its $10.6 billion acquisition of Nuvalent earlier this year. The green light is GSK's third high-profile regulatory win in recent weeks.

Nelkarmi targets a bigger crowd than GSK's first lung cancer approval, Jideytro, which the FDA cleared in July for ROS1-positive NSCLC. Hesham Abdullah, GSK's global head of oncology R&D, told reporters that ALK-positive patients make up roughly 4% of NSCLC cases, while ROS1-positive disease accounts for an estimated 1% to 2%. When Royalty Pharma bought a royalty interest in both drugs at the end of 2025, it pointed to analysts' consensus projections of $3.5 billion in Nelkarmi sales by 2035, against $1.9 billion for Jideytro.

Sponsored

The accelerated approval covers a narrow slice of patients for now: those who have already taken Roche's Alecensa, or at least two ALK inhibitors plus platinum-based chemotherapy. It arrived ahead of the FDA's original decision date of Nov. 27, backed by the phase 1/2 Alkove-1 trial. In that study, second-line patients who started on Alecensa posted a 49% overall response rate, with 52% of responses lasting at least a year; those who had tried two or more prior ALK drugs and chemo hit 32%, with 51% of responses lasting at least a year. Among patients with measurable brain metastases, intracranial response rates were 55% and 26%, with complete responses in 25% and 11%.

Nelkarmi is launching into a crowded ALK market against Roche's Alecensa and Pfizer's Lorbrena, both blockbusters by 2025 sales. At the ASCO 2026 annual meeting this summer, invited discussant Angel Qin, M.D., of the University of Michigan, called Nelkarmi's 26% response rate in post-Lorbrena patients ''modest,'' stirring investor jitters. Nuvalent pushed back that the label shouldn't apply to a Lorbrena comparison, according to a June 5 Jefferies note, which cited a median progression-free survival of 14.5 months in previously treated patients who hadn't taken Lorbrena — two to three times Lorbrena's showing in a comparable second-line setting. GSK unveiled its $10.6 billion Nuvalent deal days after the ASCO presentation.

Tolerability is GSK's other pitch. Lorbrena is known for neurological side effects that can disrupt treatment, while Nelkarmi was designed to be more specific for ALK and to spare the TrkB kinase, cutting central nervous system effects — a key consideration since ALK-positive NSCLC often strikes people in their 40s and 50s, Abdullah said. Jefferies analysts have called the CNS profile ''highly favorable,'' with no cognitive or mood effects. In Alkove-1, 5% of patients stopped Nelkarmi permanently because of adverse reactions, with liver toxicity the leading cause. ''As patients move through multiple therapies over the course of their disease, they need options that balance durable disease control with the ability to tolerate and remain on treatment and maintain quality of life,'' Kirk Smith, president of patient organization ALK Positive, said in a statement provided by GSK.

GSK is now testing Nelkarmi in the first-line Alkazar trial, with Alecensa as the comparator. Even as Lorbrena gains ground as a third-generation option, Abdullah noted Alecensa is still used in about 45% of first-line patients, and it also holds an FDA nod as an adjuvant treatment after tumor resection in early-stage ALK-positive NSCLC. Abdullah said GSK will consider Nelkarmi's potential in earlier-stage disease too. The Nelkarmi nod follows the Oct. 19 approval of GSK's PD-1 inhibitor Jemperli as the first immunotherapy for stage 2 and 3 locally advanced rectal cancer that is microsatellite instability-high or mismatch repair deficient, and the next day's clearance of Hibsago as the first antisense oligonucleotide for chronic hepatitis B.

TopicsGSK · Nelkarmi · Nuvalent · Jideytro · FDA · Pfizer · Roche · Royalty Pharma

Share

Source: fiercepharma.com

Written by AI from verified reporting.

More stories

  • Health & science 33 minutes ago · medicalxpress.com · 1 view
    FDA clears Sunharbo, first factor XIa inhibitor to prevent second strokes
  • Health & science 1 hour ago · medicalxpress.com · 1 view
    FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
  • Health & science 4 hours ago · france24.com · 1 view
    WHO warns drug resistance is outpacing the world's response
  • Health & science 7 hours ago · aol.com · 2 views
    FDA Approves Beren's LEMBAZ, First Drug to Improve Survival in Infantile NPC
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.